109.44
price up icon3.13%   3.32
after-market Dopo l'orario di chiusura: 108.00 -1.44 -1.32%
loading
Precedente Chiudi:
$106.12
Aprire:
$105.41
Volume 24 ore:
754.22K
Relative Volume:
0.63
Capitalizzazione di mercato:
$6.84B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
15.41
EPS:
7.1
Flusso di cassa netto:
$1.10B
1 W Prestazione:
+1.23%
1M Prestazione:
+1.27%
6M Prestazione:
-11.13%
1 anno Prestazione:
+2.79%
Intervallo 1D:
Value
$105.26
$111.25
Intervallo di 1 settimana:
Value
$105.26
$111.25
Portata 52W:
Value
$95.49
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
Nome
Jazz Pharmaceuticals Plc
Name
Telefono
353-1-634-7800
Name
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
Dipendente
2,800
Name
Cinguettio
@jazzpharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
JAZZ's Discussions on Twitter

Confronta JAZZ con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
109.44 6.84B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-07 Aggiornamento UBS Neutral → Buy
2025-02-26 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-02-13 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-12-12 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-06-05 Iniziato Goldman Buy
2024-01-03 Iniziato Robert W. Baird Outperform
2023-11-27 Downgrade UBS Buy → Neutral
2023-09-29 Iniziato Raymond James Mkt Perform
2023-06-12 Ripresa Wells Fargo Equal Weight
2022-12-09 Aggiornamento Goldman Neutral → Buy
2022-06-14 Iniziato UBS Buy
2022-04-06 Downgrade Goldman Buy → Neutral
2021-11-19 Ripresa Goldman Buy
2021-10-07 Ripresa Jefferies Buy
2021-10-05 Iniziato Citigroup Buy
2021-09-23 Iniziato Needham Buy
2021-05-19 Ripresa JP Morgan Overweight
2021-04-07 Ripresa RBC Capital Mkts Outperform
2021-02-05 Reiterato H.C. Wainwright Buy
2021-02-03 Aggiornamento Piper Sandler Neutral → Overweight
2021-01-29 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-12-16 Iniziato UBS Buy
2020-11-03 Reiterato H.C. Wainwright Buy
2020-10-09 Reiterato H.C. Wainwright Buy
2020-09-14 Downgrade Goldman Neutral → Sell
2020-09-14 Ripresa JP Morgan Overweight
2020-08-06 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-07-28 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-07-23 Aggiornamento H.C. Wainwright Neutral → Buy
2020-04-06 Iniziato Jefferies Buy
2020-03-12 Aggiornamento Bernstein Mkt Perform → Outperform
2020-01-08 Iniziato Goldman Neutral
2019-08-21 Downgrade Piper Jaffray Overweight → Neutral
2019-06-11 Iniziato Barclays Overweight
2019-03-20 Iniziato SunTrust Buy
2018-12-14 Iniziato Wolfe Research Peer Perform
2018-11-08 Reiterato B. Riley FBR Buy
2018-08-08 Reiterato Stifel Buy
2018-07-11 Downgrade Morgan Stanley Overweight → Equal-Weight
2018-03-23 Reiterato H.C. Wainwright Neutral
2018-03-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
Mostra tutto

Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie

pulisher
Jun 19, 2025

FDA Approvals and Clinical Trials Impacting Narcolepsy - openPR.com

Jun 19, 2025
pulisher
Jun 13, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jun 13, 2025
pulisher
Jun 12, 2025

Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com

Jun 12, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®. - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals (JAZZ) Stock Ratings Reiterated by Needham - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Transcript : Jazz Pharmaceuticals plcSpecial Call - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

FDA Fast-Tracks Jazz Pharmaceuticals' Lung Cancer Drug Application - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharma stock gains on FDA review for lung cancer therapy - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharmaceuticals (JAZZ) Awaits FDA Decision on Lung Cancer Treatment | JAZZ Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

FDA Fast-Tracks Revolutionary Lung Cancer Drug That Cuts Disease Progression Risk by 46% - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Parallel Advisors LLC Acquires 119 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals (JAZZ) Reveals New Findings on Xywav at SLE - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcas - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PR Newswire

Jun 09, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals' Xywav Achieves 4.1 mmHg Blood Pressure Reduction in Groundbreaking Phase 4 Trial - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

Transcript : Jazz Pharmaceuticals plc Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

May 2026 Options Now Available For Jazz Pharmaceuticals - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer StudyJazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Jazz Pharmaceuticals (JAZZ) Maintains Buy Rating with $202 Price Target | JAZZ Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reports Positive Results for Zepzelc - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Resu - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Results for Zepzelca | JAZZ Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Zepzelca combo extends survival in lung cancer study - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Phase 3 Trial: Zepzelca Combo Cuts Lung Cancer Progression Risk by 46% | JAZZ Stock News - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reports Promising Long-term Data for Ziihera | JAZZ Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA - StreetInsider

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PR Newswire

Jun 02, 2025
pulisher
May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.

May 30, 2025
pulisher
May 29, 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Jazz Pharmaceuticals Reveals 19 New Xywav Studies for Sleep Disorders at SLEEP 2025 | JAZZ Stock News - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire

May 29, 2025

Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Jazz Pharmaceuticals Plc Azioni (JAZZ) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
COZADD BRUCE C
Chairman & CEO
Jun 02 '25
Sale
107.90
500
53,950
438,473
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):